Journal of AdvancedMedical and Dental Sciences Research

Background: Chronic obstructive pulmonary disease is a chronic respiratory disease characterized by a decline in lung function over time and accompanied by respiratory symptoms, primarily dyspnea, cough, and sputum production. The present study was conducted to determine effect of rosuvastatin in patients of COPD. Materials & Methods: 56 patients of COPD of both genders were divided into 2 groups. Group I received rosuvastatin 10 mg orally once daily and group II received placebo matching the active drug. In all patients, forced vital capacity (FVC), forced expiratory volume at 1 second (FEV1), FEV1/FVC, and peak expiratory flow rate (PEFR) was recorded. Results: The mean age in group I was 61.2 years and in group II was 63.4 years, BMI was 19.2 kg/m2 in group I and 18.7 kg/m2 in group II, heart beat was 84.5 beats/minute in group I and 89.2 beats/minute in group II. The difference was non- significant (P> 0.05). There was significant increase in FEV1 and FEV1/FVC in group II as compared to group I (P< 0.05). Conclusion: Authors found that rosuvastatin found to be better in COPD patients in reducing FVC, FEV1, FEV1/FVC as compared to placebo. Key words: COPD, Peak expiratory flow rate, Rosuvastatin